Back to Search
Start Over
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
- Source :
- Modern Pathology, 28, 1297-314, Liu, Z, Xu-Monette, Z Y, Cao, X, Manyam, G C, Wang, X, Tzankov, A, Xia, Y, Li, X, Visco, C, Sun, R, Zhang, L, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, K L, Hsi, E D, Choi, W W, van Krieken, J H, Huh, J, Ponzoni, M, Ferreri, A J, Parsons, B M, Møller, M B, Piris, M A, Winter, J N, O'Malley, D P, Medeiros, L J & Young, K H 2015, ' Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy ', Modern Pathology, vol. 28, no. 10, pp. 1297-1314 . https://doi.org/10.1038/modpathol.2015.94, Modern Pathology, 28, 10, pp. 1297-314
- Publication Year :
- 2015
-
Abstract
- Contains fulltext : 153740.pdf (Publisher’s version ) (Closed access) Survivin, a member of the inhibitor of apoptosis protein family, is overexpressed in a variety of human neoplasms. The prognostic significance of survivin expression in diffuse large B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is unclear. We used standard immunohistochemistry methods to quantify survivin expression in 463 patients with de novo diffuse large B-cell lymphoma who received the R-CHOP. Of the 463 patients, 269 (58%) had survivin overexpression with a cutoff of >25%, associated with an International Prognostic Index score of >2 (P=0.015), disease in >/=2 extranodal sites (P=0.011), and a high Ki-67 index (P
- Subjects :
- Male
Pathology
Lymphoma
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Survivin
Kaplan-Meier Estimate
CHOP
Inhibitor of Apoptosis Proteins
Antibodies, Monoclonal, Murine-Derived
International Prognostic Index
Monoclonal
Antineoplastic Combined Chemotherapy Protocols
80 and over
Medicine
B-cell lymphoma
Aged, 80 and over
Tumor
Middle Aged
Prognosis
Immunohistochemistry
Diffuse
Vincristine
Rituximab
Female
Lymphoma, Large B-Cell, Diffuse
medicine.drug
Adult
Murine-Derived
medicine.medical_specialty
Adolescent
Antibodies
Disease-Free Survival
Pathology and Forensic Medicine
Young Adult
Biomarkers, Tumor
Large B-Cell
Humans
Cyclophosphamide
Aged
Proportional Hazards Models
business.industry
medicine.disease
Doxorubicin
Tissue Array Analysis
Prednisone
business
Transcriptome
Diffuse large B-cell lymphoma
Biomarkers
Subjects
Details
- Language :
- English
- ISSN :
- 08933952
- Database :
- OpenAIRE
- Journal :
- Modern Pathology, 28, 1297-314, Liu, Z, Xu-Monette, Z Y, Cao, X, Manyam, G C, Wang, X, Tzankov, A, Xia, Y, Li, X, Visco, C, Sun, R, Zhang, L, Montes-Moreno, S, Dybkær, K, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, K L, Hsi, E D, Choi, W W, van Krieken, J H, Huh, J, Ponzoni, M, Ferreri, A J, Parsons, B M, Møller, M B, Piris, M A, Winter, J N, O'Malley, D P, Medeiros, L J & Young, K H 2015, ' Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy ', Modern Pathology, vol. 28, no. 10, pp. 1297-1314 . https://doi.org/10.1038/modpathol.2015.94, Modern Pathology, 28, 10, pp. 1297-314
- Accession number :
- edsair.doi.dedup.....2cb46f1dd93029d6ba6e463469c75ae1